Zealand Pharma agrees to sell V-Go insulin delivery device to MannKind Corporation.
Zealand Pharma announced it has entered into an asset purchase agreement with MannKind Corporation ( to sell the V-Go insulin delivery device for $10 million and additional sales-based milestones).
Certain inventory and employees are also included under the terms of the agreement.
V-Go is a once-daily, wearable, insulin delivery device that helps provide blood sugar control for everyday lifestyles. Designed to be patient-friendly, V-Go is worn like a patch and eliminates the need for taking multiple daily shots. The acquisition of V-Go by MannKind is anticipated to close in May 2022, subject to the satisfaction of certain closing conditions.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins